Combing Model Coarse Graining, Optimal Design and Quantitative Risk Assessment for Simulating Adaptive Clinical Trials

被引：0
|
作者：
Jentsch, Garrit [1 ]
Austin, Rupert [1 ]
Hayman, Aaron [1 ]
Grevel, Joachim [1 ]
机构：
[1] BAST Inc Ltd, Loughborough, Leics, England
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2014年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
M-053
引用
收藏
页码：S30 / S30
页数：1
相关论文
共 31 条
  • [21] Quantitative plaque characterization with coronary CT angiography (CTA)Current challenges and future application in atherosclerosis trials and clinical risk assessment
    Paul Schoenhagen
    Mitya Barreto
    Sandra S. Halliburton
    The International Journal of Cardiovascular Imaging, 2008, 24 (3) : 313 - 316
  • [22] A Bayesian Dynamic Model-Based Adaptive Design for Oncology Dose Optimization in Phase I/II Clinical Trials
    Qiu, Yingjie
    Li, Mingyue
    PHARMACEUTICAL STATISTICS, 2025, 24 (02)
  • [23] An adaptive design for the identification of the optimal dose using joint modelling of efficacy and toxicity in phase I/II clinical trials of molecularly targeted agents
    Altzerinakou, Maria
    Paoletti, Xavier
    TRIALS, 2017, 18
  • [24] Visual Communication of Safety Data in Ongoing Studies: The Adaptive Benefit-Risk Assessment tool for Clinical Trials (ABRA-CTV)
    Bond, T. C.
    Rayavaram, S.
    Dan, S.
    Vaidya, I.
    DRUG SAFETY, 2022, 45 (10) : 1117 - 1118
  • [25] WHAT DETERMINES PROGNOSIS IN SEPSIS - EVIDENCE FOR A COMPREHENSIVE INDIVIDUAL PATIENT RISK ASSESSMENT APPROACH TO THE DESIGN AND ANALYSIS OF CLINICAL-TRIALS - DISCUSSION
    KNAUS, WA
    WAGNER, DP
    HARRELL, FE
    DRAPER, EA
    THEORETICAL SURGERY, 1994, 9 (01): : 20 - 27
  • [26] An adaptive design for the identification of the optimal dose using joint modeling of continuous repeated biomarker measurements and time-to-toxicity in phase I/II clinical trials in oncology
    Altzerinakou, Maria-Athina
    Paoletti, Xavier
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2020, 29 (02) : 508 - 521
  • [27] Risk-based quality by design (QbD): A Taguchi perspective on the assessment of product quality, and the quantitative linkage of drug product parameters and clinical performance
    Cogdill R.P.
    Drennen J.K.
    Journal of Pharmaceutical Innovation, 2008, 3 (1) : 23 - 29
  • [28] A Quantitative Systems Pharmacology Model of Glucose-Insulin Regulation to Guide the Design and Evaluation of Novel Basal Insulins with Optimal Risk-Benefit Profile
    Geiser, Jeanne
    Garhyan, Parag
    Chien, Jenny
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S53 - S53
  • [29] Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the "CiPA" Initiative and Design of a Prospective Clinical Validation Study
    Vicente, Jose
    Zusterzeel, Robbert
    Johannesen, Lars
    Mason, Jay
    Sager, Philip
    Patel, Vikram
    Matta, Murali K.
    Li, Zhihua
    Liu, Jiang
    Garnett, Christine
    Stockbridge, Norman
    Zineh, Issam
    Strauss, David G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (01) : 54 - 66
  • [30] Automatic quantitative stroke severity assessment based on Chinese clinical named entity recognition with domain-adaptive pre-trained large language model
    Gu, Zhanzhong
    He, Xiangjian
    Yu, Ping
    Jia, Wenjing
    Yang, Xiguang
    Peng, Gang
    Hu, Penghui
    Chen, Shiyan
    Chen, Hongjie
    Lin, Yiguang
    ARTIFICIAL INTELLIGENCE IN MEDICINE, 2024, 150
1234